dsm-firmenich Advances €1.08 Billion Share Repurchase Program

Company Nears Completion Following Sale of Feed Enzymes Alliance Stake

dsm-firmenich, a global innovator in nutrition, health, and beauty, continues to advance its €1.08 billion share repurchase program, with the latest update confirming significant progress toward completion. The program, which aims to repurchase and cancel ordinary shares to reduce the company’s issued capital, is scheduled for completion no later than January 30, 2026.

The initiative was first announced on February 13, 2025, when dsm-firmenich revealed plans to repurchase ordinary shares with a total market value of €1 billion, beginning with an initial tranche of €500 million. The company formally launched the program on April 1, 2025, repurchasing up to €580 million worth of shares — comprising €80 million to cover commitments under its share-based compensation plans and €500 million designated for capital reduction.

Following the successful sale of dsm-firmenich’s stake in the Feed Enzymes Alliance, the company announced on June 27, 2025, an increase in the total value of the share repurchase program to €1.08 billion. This expansion reflected both strengthened financial flexibility and continued confidence in the company’s strategic direction.

In its most recent market update, dsm-firmenich reported that during the period from October 27 to October 31, 2025, it repurchased 441,421 ordinary shares at an average price of €73.00 per share, representing a total value of €32.2 million. To date, the company has repurchased a total of 11,097,500 shares under the ongoing program, at an average price of €85.62 per share, for a total consideration of €950.1 million.

The share repurchase program underscores dsm-firmenich’s commitment to disciplined capital allocation and shareholder value creation, while maintaining a strong balance sheet to support future growth initiatives. The company reiterated that the program will be finalized by January 30, 2026, aligning with its broader strategic focus on enhancing long-term value for investors and supporting sustainable business performance across its global operations.